Literature DB >> 16307300

Carcinomatous meningitis from urachal carcinoma: the first reported case.

Shearwood McClelland1, Rebeca E Garcia, Sara E Monaco, James E Goldman, Ty J Olson, Grace H Kim, Daniel P Petrylak, Robert R Goodman.   

Abstract

Carcinomatous meningitis (CM) occurs in less than 10% of cancer patients. Although patients frequently present with a focal complaint, multifocal signs are often found following careful neurological examination. The gold standard for diagnosis remains the demonstration of neoplastic cells in the cerebrospinal fluid. Despite the discouraging prognosis, palliative treatment may improve quality of life and lengthen lifespan. We report a patient with known primary carcinoma of the urachus who presented with headaches, nausea, vomiting and ataxia 1 week following resection of a nodular arachnoidal metastasis (indenting the cerebellum). Lumbar cerebrospinal fluid subsequently confirmed carcinomatous meningitis. This is the first reported case of carcinomatous meningitis resulting from metastatic urachal carcinoma.

Entities:  

Mesh:

Year:  2006        PMID: 16307300     DOI: 10.1007/s11060-005-4815-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?

Authors:  M J Glantz; B F Cole; L Recht; W Akerley; P Mills; S Saris; F Hochberg; P Calabresi; M J Egorin
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

Review 2.  Current options for the treatment of neoplastic meningitis.

Authors:  Ilkcan Cokgor; Allan H Friedman; Henry S Friedman
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

3.  Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain.

Authors:  M C Chamberlain; A D Sandy; G A Press
Journal:  Neurology       Date:  1990-03       Impact factor: 9.910

Review 4.  Leptomeningeal carcinomatosis.

Authors:  S A Grossman; M J Krabak
Journal:  Cancer Treat Rev       Date:  1999-04       Impact factor: 12.111

5.  Brain metastasis from urachal carcinoma.

Authors:  S Fujiwara; T Takaki; T Hikita; H Kanzaki; S Kuroiwa
Journal:  Surg Neurol       Date:  1988-06

6.  Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias.

Authors:  J G Kaplan; T G DeSouza; A Farkash; B Shafran; D Pack; F Rehman; J Fuks; R Portenoy
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

7.  Urachal carcinoma: CT findings.

Authors:  S H Brick; A C Friedman; H M Pollack; E K Fishman; P D Radecki; M H Siegelbaum; D G Mitchell; A S Lev-Toaff; D F Caroline
Journal:  Radiology       Date:  1988-11       Impact factor: 11.105

8.  Computed tomographic appearance of urachal adenocarcinomas: review of 25 cases.

Authors:  Cornelia M Thali-Schwab; Paula J Woodward; Brent J Wagner
Journal:  Eur Radiol       Date:  2004-07-17       Impact factor: 5.315

9.  Clinical outcome in aggressively treated meningeal carcinomatosis.

Authors:  R Grant; B Naylor; H S Greenberg; L Junck
Journal:  Arch Neurol       Date:  1994-05

10.  Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.

Authors:  M J Glantz; W A Hall; B F Cole; B S Chozick; C M Shannon; L Wahlberg; W Akerley; L Marin; H Choy
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

View more
  2 in total

1.  Metastatic urachal carcinoma in bronchial brush cytology.

Authors:  Fatima Zahra Aly; Abeer Z Tabbarah; Lysandra Voltaggio
Journal:  Cytojournal       Date:  2013-01-31       Impact factor: 2.091

Review 2.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.